Generation Bio to Present at the JMP Securities Life Sciences Conference
09 June 2021 - 9:30PM
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines
company creating a new class of non-viral gene therapy, announced
today that Geoff McDonough, M.D., president and chief executive
officer, will present at the JMP Securities Life Sciences
Conference on Wednesday, June 16, at 11:30 a.m. ET.
A live webcast of the presentation will be available on the
investor section of the company’s website at
investors.generationbio.com. A replay will be available there for
30 days following the event.
About Generation Bio
Generation Bio is an innovative genetic medicines company
focused on creating a new class of non-viral gene therapy to
provide durable, redosable treatments for people living with rare
and prevalent diseases. The company’s non-viral platform
incorporates a proprietary, high-capacity DNA construct called
closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle
delivery system, or ctLNP; and an established, scalable capsid-free
manufacturing process. The platform is designed to enable
multi-year durability from a single dose of ceDNA and to allow
titration and redosing if needed. The ctLNP is designed to deliver
large genetic payloads, including multiple genes, to specific
tissues to address a wide range of indications. The company’s
efficient, scalable manufacturing process supports Generation Bio’s
mission to extend the reach of gene therapy to more people, living
with more diseases, in more places around the world.
For more information, please
visit www.generationbio.com.
Contact:
Investors Maren KillackeyGeneration
Biomkillackey@generationbio.com541-646-2420
Media Alicia WebbGeneration
Bioawebb@generationbio.com847-254-4275
Stephanie Simon Ten Bridge
Communicationsstephanie@tenbridgecommunications.com617-581-9333
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From May 2023 to May 2024